Biohaven Pharmaceuticals will advance its newly acquired COVID-19 treatment into human testing after lab studies showed it worked against multiple strains of the coronavirus — including the new and more worrisome variants.
The New Haven drug maker says preliminary experiments found its synthetic antibody-based treatment, BHV-1200, substantially reduced the virus’ entry into cells.